Antengene Completes $340 Million Hong Kong IPO for Oncology Drugs
publication date: Nov 20, 2020
Shanghai Antengene, a three-year old oncology company, completed a $340 million IPO in Hong Kong. The company, which was originally backed by Celgene, said the offering was significantly oversubscribed. Antengene has built a portfolio of 12 first-in-class, only-in-class and best-in-class cancer therapies, six of which have begun clinical trials. It combines in-licensings with internal research. The company says it uses a synergistic approach to "unlock the full therapeutic potential" of its candidates. More details....
Stock Symbol: (HK: 6996)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.